Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

InDex Pharmaceuticals receives first regulatory approval to start the phase III study CONCLUDE with cobitolimod

July 21, 2021 – InDex Pharmaceuticals Holding AB (publ) today announced that the Swedish Medical Products Agency (MPA) has given approval to start the phase III clinical study CONCLUDE in Sweden. The study will evaluate the efficacy and safety of the first-in-class TLR9 agonist cobitolimod for the treatment of moderate to severe left-sided ulcerative colitis.“We are very pleased to have received approval from the MPA to start the phase III study CONCLUDE with cobitolimod, and we plan to initiate patient recruitment in Sweden and other countries after the summer,” said Peter Zerhouni, CEO of

Norway Royal Salmon ASA (NRS): Mandatory notification of trade

NTS ASA ("NTS") has on 21 July 2021 purchased through the market 20,420 shares in Norway Royal Salmon ASA ("NRS") at an average price of NOK 209 per share. No shares were purchased at a price higher than the offer price in the mandatory offer. Following completion of these transactions, NTS controls directly and indirectly through Midt-Norsk Havbruk AS 14,041,577 shares in NRS, equal to 32.23% of the total number of issued and outstanding shares in NRS. Held together with the 1,624,607 shares that NTS shall acquire from Gåsø Næringsutvikling AS, NTS will control 15,666,184 shares in NRS,

Director/PDMR Shareholding

21 July 2021 15:50 BST Transaction by Person Discharging Managerial Responsibilities AstraZeneca PLC (the Company) announced that on 21 July 2021, Marc Dunoyer, Chief Financial Officer, received 21,243 Ordinary Shares of $0.25 each in the Company (Ordinary Shares). The Ordinary Shares were issued to Mr Dunoyer on completion of the Company's acquisition of Alexion Pharmaceuticals, Inc. (Alexion) as part consideration for the 20,000 Alexion shares held by Mr Dunoyer at the time of completion. In accordance with the Agreement and Plan of Merger entered into by the Company on 12

Media invitation – Press conference on expansion investment Boliden Odda

Boliden has decided to invest EUR 700 m in Boliden Odda during the coming years. The intent is to increase annual production to 350 ktonnes and to produce by-products lead, gold and silver. At the press conference, Boliden’s President and CEO Mikael Staffas and General Manager at Boliden Odda Helene Seim will be available for media.   Date: 22 July. Time: 11.30 CET  The press conference is held in Swedish/Norwegian. To participate, please call 5 minutes before the opening of the conference:Link: https://boliden.videosync.fi/2021-07-22-pressmeeting_2021Tel:  · From Norway

Stena RoRo orders its tenth E-Flexer RoPax ferry

Stena RoRo is pleased to have executed a new charter agreement with Marine Atlantic, a Canadian federal Crown corporation. As a result, Stena has ordered its tenth E-Flexer vessel from the CMI Jinling (Weihai) shipyard.  The ship, when delivered, will run in eastern Canada between Newfoundland and Nova Scotia. Delivery from the shipyard is expected during 2024. "Marine Atlantic is a former customer of ours," says Per Westling, managing director for Stena RoRo. "We delivered one ferry in 2000 and two more in 2010 to Marine Atlantic, all of which are still in service. We were

Total Voting Rights

21 July 2021 15:45 BST     Transparency Directive Voting rights and capital The following notification is made in accordance with the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1. As at 21 July 2021 the issued share capital of AstraZeneca PLC with voting rights is 1,549,116,129 ordinary shares of US$0.25. No shares are held in Treasury. Therefore, the total number of voting rights in AstraZeneca PLC is 1,549,116,129.   The above figure for the total number of voting rights may be used by shareholders as the denominator for the calculations by

Boliden’s second quarter: Strong earnings and cash flow

Sales for the second quarter totaled SEK 17,891 m (13,391) and operating profit excluding revaluation of process inventory was SEK 2,616 m (1,634). Free cash flow totaled SEK 2,013 m (1,174).“The need and demand for base metals in connection with climate transition are becoming increasingly clear. At the same time, improved prices for Boliden’s metals means that earnings from mining operations in particular are developing positively, especially at the three mines we recently expanded,” says Mikael Staffas, President and CEO. Operating profit at Boliden Mines increased to SEK 2,192 m (779)

Q2 Interim Report 2021

Q2 2021 · Revenues totaled SEK 17,891 m (13,391)  · The operating profit totaled SEK 2,785 m (1,801) · The operating profit, excluding revaluation of process inventory, totaled SEK 2,616 m (1,634) · Free cash flow totaled SEK 2 013 m (1 174) · Earnings per share totaled SEK 8.00 (4.92) Strong earnings and cash flow · High metal prices. · Stable production in both Mines and Smelters. · The Board has decided to invest EUR 700 m in the smelter in Odda to increase capacity from 200 to 350 ktonnes /year. Please find enclosed the full report. The Interim

Notification under Chapter 9, Section 10 of the Finnish Securities Market Act: holdings of BlackRock in Neste Corporation exceeded 5%

Neste Corporation, Stock Exchange Release, 21 July 2021 at 5.30 p.m. (EET)Neste Corporation has today received a notification under Chapter 9, Section 10 of the Finnish Securities Market Act (FSMA). According to the notification by BlackRock, Inc., the aggregate holdings of the entities referred to therein in Neste Corporation have on 20 July 2021 exceeded 5% of the total number of shares and voting rights of Neste Corporation.According to the notification received by Neste Corporation, the holdings of BlackRock in Neste Corporation on 20 July 2021 amounted to a total of 38,509,054

Expansion of Boliden Odda and more zinc with world-leading climate performance

Boliden has decided to invest in the expansion of Boliden Odda in Norway to an annual zinc production of 350 Ktonnes. The investment is for a total of EUR 700 m and will be completed at the end of 2024. The expansion means that the production of zinc with world-leading climate performance will almost double.Today, Boliden Odda has an annual production capacity of 200 Ktonnes of zinc. The operation will be supplied with fossil-free electricity, and waste deposition will take place in mountin caverns using unique, sustainable technology. The investment will mean an increase in the annual

Publication of Registration Document

Regulatory Announcement  Royal Bank of CanadaJuly 21, 2021 Publication of Registration Document Not for release, publication or distribution, directly or indirectly, in or into the United States. The following registration document has been approved by the Financial Conduct Authority and, along with the documents incorporated by reference therein, is available for viewing: Registration Document dated July 21, 2021 relating to Royal Bank of Canada. The Registration Document, together with the documents incorporated by reference therein, have been submitted to the

#21-244 Listing of Derivatives at NGM

Information about various derivatives that will be listed at NGM.For more details, see attached file. For further information concerning this NGM notice please contact NGM Listing department on phone +46 8 566 390 20 or listings@ngm.se. Nordic Growth Market NGM AB About NGMNordic Growth Market NGM AB (NGM) is an authorized stock exchange with operations in Sweden, Norway, Denmark and Finland. The exchange is a wholly-owned subsidiary of Boerse Stuttgart, the leading retail exchange in Germany. NGM offers a complete marketplace for exchange traded products and provides a

Wärtsilä Corporation - Manager's transaction: Agnevall, Håkan

Wärtsilä Corporation, Managers' transactions, 21 July 2021 at 17:00 EESTWärtsilä Corporation - Managers' Transactions____________________________________________ Person subject to the notification requirementName: Agnevall, HåkanPosition: Chief Executive OfficerIssuer: Wärtsilä CorporationLEI: 743700G7A9J1PHM3X223 Notification type: INITIAL NOTIFICATIONReference number: 743700G7A9J1PHM3X223_20210721160238_16____________________________________________ Transaction date: 2021-07-21Venue: XHELInstrument type: SHAREISIN: FI0009003727Nature of the transaction:

HKScan Corporation - Managers' Transactions - Kiskola

HKScan Corporation, Managers' transactions, 21 July 2021 at 4.00 p.m. EETHKScan Corporation - Managers' Transactions - Kiskola____________________________________________Person subject to the notification requirementName: Kiskola, ReijoPosition: Member of the Board/Deputy memberIssuer: HKScan OyjLEI: 7437000PN6E448NPGY86Notification type: INITIAL NOTIFICATIONReference number: 7437000PN6E448NPGY86_20210721130636_18____________________________________________Transaction date: 2021-07-20Venue: NASDAQ HELSINKI LTD (XHEL)Instrument type: SHAREISIN: FI0009006308Nature

Securitas AB to publish the Interim report January-June 2021 on July 29

Securitas AB will publish the Interim report for January-June 2021 on Thursday, July 29, 2021, at approximately 1.00 p.m. (CET).App. 1.00 p.m. (CET) Report release The report will be sent as a press release from Cision (www.cision.se) and will automatically be published on www.securitas.com when released.2.00 p.m. (CET) Presentation slides available For presentation slides, follow the link www.securitas.com/presentations   2.30 p.m. (CET) Telephone conference and audio castAnalysts and media are invited to participate in a telephone conference at 2.30 p.m. (CET) where Securitas

HKScan Corporation - Managers' Transactions - Leskelä

HKScan Corporation, Managers' transactions, 21 July 2021 at 4.00 p.m. EETHKScan Corporation - Managers' Transactions - Leskelä____________________________________________Person subject to the notification requirementName: Leskelä, AnnePosition: Member of the Board/Deputy memberIssuer: HKScan OyjLEI: 7437000PN6E448NPGY86Notification type: INITIAL NOTIFICATIONReference number: 7437000PN6E448NPGY86_20210721114907_16____________________________________________Transaction date: 2021-07-20Venue: NASDAQ HELSINKI LTD (XHEL)Instrument type: SHAREISIN: FI0009006308Nature

HKScan Corporation - Managers' Transactions - Mäkilä

HKScan Corporation, Managers' transactions, 21 July 2021 at 4.00 p.m. EETHKScan Corporation - Managers' Transactions - Mäkilä____________________________________________Person subject to the notification requirementName: Mäkilä, JariPosition: Member of the Board/Deputy memberIssuer: HKScan OyjLEI: 7437000PN6E448NPGY86Notification type: INITIAL NOTIFICATIONReference number: 7437000PN6E448NPGY86_20210721114701_16____________________________________________Transaction date: 2021-07-20Venue: NASDAQ HELSINKI LTD (XHEL)Instrument type: SHAREISIN: FI0009006308Nature of

HKScan Corporation - Managers' Transactions - Nyman

HKScan Corporation, Managers' transactions, 21 July 2021 at 4.00 p.m. EETHKScan Corporation - Managers' Transactions - Nyman____________________________________________Person subject to the notification requirementName: Nyman, Per OlofPosition: Member of the Board/Deputy memberIssuer: HKScan OyjLEI: 7437000PN6E448NPGY86Notification type: INITIAL NOTIFICATIONReference number: 7437000PN6E448NPGY86_20210721115359_16____________________________________________Transaction date: 2021-07-20Venue: NASDAQ HELSINKI LTD (XHEL)Instrument type: SHAREISIN: FI0009006308Nature

HKScan Corporation - Managers' Transactions - Suutari

HKScan Corporation, Managers' transactions, 21 July 2021 at 4.00 p.m. EETHKScan Corporation - Managers' Transactions - Suutari____________________________________________Person subject to the notification requirementName: Suutari, HarriPosition: Member of the Board/Deputy memberIssuer: HKScan OyjLEI: 7437000PN6E448NPGY86Notification type: INITIAL NOTIFICATIONReference number: 7437000PN6E448NPGY86_20210721115222_16____________________________________________Transaction date: 2021-07-20Venue: NASDAQ HELSINKI LTD (XHEL)Instrument type: SHAREISIN: FI0009006308Nature

HKScan Corporation - Managers' Transactions - Thorwid

HKScan Corporation, Managers' transactions, 21 July 2021 at 4.00 p.m. EETHKScan Corporation - Managers' Transactions - Thorwid____________________________________________Person subject to the notification requirementName: Thorwid, Carl-PeterPosition: Member of the Board/Deputy memberIssuer: HKScan OyjLEI: 7437000PN6E448NPGY86Notification type: INITIAL NOTIFICATIONReference number: 7437000PN6E448NPGY86_20210721115531_16____________________________________________Transaction date: 2021-07-20Venue: NASDAQ HELSINKI LTD (XHEL)Instrument type: SHAREISIN: FI0009006308

HKScan Corporation - Managers' Transactions - Tuomi

HKScan Corporation, Managers' transactions, 21 July 2021 at 4.00 p.m. EETHKScan Corporation - Managers' Transactions - Tuomi____________________________________________Person subject to the notification requirementName: Tuomi, TerhiPosition: Member of the Board/Deputy memberIssuer: HKScan OyjLEI: 7437000PN6E448NPGY86Notification type: INITIAL NOTIFICATIONReference number: 7437000PN6E448NPGY86_20210721115055_16____________________________________________Transaction date: 2021-07-20Venue: NASDAQ HELSINKI LTD (XHEL)Instrument type: SHAREISIN: FI0009006308Nature of

HKScan Corporation - Managers' Transactions - Uusitalo

HKScan Corporation, Managers' transactions, 21 July 2021 at 4.00 p.m. EETHKScan Corporation - Managers' Transactions - Uusitalo____________________________________________Person subject to the notification requirementName: Uusitalo, IlkkaPosition: Member of the Board/Deputy memberIssuer: HKScan OyjLEI: 7437000PN6E448NPGY86Notification type: INITIAL NOTIFICATIONReference number: 7437000PN6E448NPGY86_20210721115650_16____________________________________________Transaction date: 2021-07-20Venue: NASDAQ HELSINKI LTD (XHEL)Instrument type: SHAREISIN: FI0009006308

Acquisition of Alexion completed

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION. 21 July 2021 13:45 BST Acquisition of Alexion completed AstraZeneca today completed the acquisition of Alexion Pharmaceuticals, Inc. (Alexion). The closing of the acquisition marks the Company's entry into medicines for rare diseases and the beginning of a new chapter for AstraZeneca. AstraZeneca now has an enhanced scientific presence in immunology and,

The game changer that is employee generated content (EGC)

Brands today are well aware of the power of social media and user generated content (UGC); it's a necessity when it comes to increasing awareness, bolstering sales, and building a community. Asking for and reposting UGC online is an effective way to showcase authentic social proof from end-users. But what if we told you there was another type of content, just waiting to be collected and used? Enter EGC: employee generated content! How EGC differs from UGCEGC is similar to UGC, however, EGC stems from employees and, sometimes, brands themselves (brand-generated content needs to feel

There are no items matching the current filter
There are no more items matching the current filter
Back to top